Athenex (ATNX) Stock Price
Athenex Price
Revenue has compounded at 74.2% per year over the past 8 years to 102.82 M USD. Athenex's net margin stands at -96.3%, up from -131.8% several years earlier. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
Athenex stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Athenex over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Athenex stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Athenex's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Athenex Price |
|---|
Athenex Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Athenex Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 13.00 | 20.00 | 38.00 | 89.00 | 101.00 | 144.00 | 120.00 | 102.00 | 102.00 | 106.00 | 152.00 | 155.00 |
| – | 1,200.00 | 53.85 | 90.00 | 134.21 | 13.48 | 42.57 | -16.67 | -15.00 | – | 3.92 | 43.40 | 1.97 |
| -1,000.00 | 200.00 | 130.00 | 31.58 | 47.19 | 30.69 | 34.03 | 30.83 | 25.49 | 25.49 | 25.49 | 25.49 | 25.49 |
| -10.00 | 26.00 | 26.00 | 12.00 | 42.00 | 31.00 | 49.00 | 37.00 | 26.00 | 26.00 | 27.02 | 38.75 | 39.51 |
| -17.00 | -50.00 | -86.00 | -125.00 | -126.00 | -119.00 | -123.00 | -114.00 | -69.00 | -54.00 | -46.00 | -4.00 | -7.00 |
| -1,700.00 | -384.62 | -430.00 | -328.95 | -141.57 | -117.82 | -85.42 | -95.00 | -67.65 | -52.94 | -43.40 | -2.63 | -4.52 |
| -17.00 | -50.00 | -87.00 | -131.00 | -117.00 | -125.00 | -148.00 | -194.00 | -98.00 | -708.00 | -239.00 | -57.00 | -79.00 |
| – | 194.12 | 74.00 | 50.57 | -10.69 | 6.84 | 18.40 | 31.08 | -49.48 | 622.45 | -66.24 | -76.15 | 38.60 |
| 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 | 157.41 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Athenex generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Athenex retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Athenex's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Athenex has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Athenex's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Athenex stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Athenex Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Athenex business model & stock analysis
Athenex SWOT Analysis
Strengths
Athenex Inc is a highly innovative biopharmaceutical company that focuses on the development and commercialization of novel cancer treatments.
The company has a strong portfolio of proprietary drugs and drug delivery technologies, giving it a competitive edge in the market.
Athenex's strategic partnerships with academic institutions and other pharmaceutical companies provide access to cutting-edge research and potential collaboration opportunities.
Weaknesses
Athenex faces the risk of high research and development costs associated with the development of new drugs, which could impact its profitability.
The company heavily relies on the success of its drug candidates, and any setbacks or failures in clinical trials could have a detrimental effect on its reputation and financial performance.
Being a relatively small biopharmaceutical company, Athenex has limited resources compared to larger competitors, which could hinder its ability to effectively compete in the market.
Opportunities
The increasing prevalence of cancer worldwide presents a significant market opportunity for Athenex, as there is a growing demand for effective cancer treatments.
Athenex can capitalize on the trend towards personalized medicine by leveraging its expertise in developing targeted therapies that cater to specific patient populations.
Expansion into international markets can provide Athenex with access to a larger customer base and diversify its revenue streams.
Threats
The biopharmaceutical industry is highly competitive, with numerous well-established players. Athenex faces the risk of intense competition, pricing pressures, and potential market saturation.
Regulatory approvals and compliance requirements pose a significant challenge for Athenex, as any delays or failures in obtaining necessary approvals can hinder the commercialization and success of its drugs.
Emerging technologies and advancements in cancer research could render Athenex's existing technologies and therapies obsolete, making it crucial for the company to stay at the forefront of innovation.
Athenex Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Athenex Segments
Athenex Revenue by Segment (1/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Segment (2/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Segment (3/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Segment (4/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Segment (5/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Segment (6/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Segment (7/7)
3 Years
5 Years
Max
Details
Athenex Revenue by Region
3 Years
5 Years
Max
Details
Athenex Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Athenex historical P/E ratio, EBIT multiple, and P/S ratio
Athenex annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Athenex shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Athenex stock splits
Current Athenex forecasts and price targets in August 2026
Analyst Price Targets 2026Athenex Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 3/21/2023 | Downgrade | BuyNeutral | 66 | |
| 5/10/2022 | Maintained | Market PerformPerform | – | |
| 3/17/2022 | Maintained | Market PerformPerform | – | |
| 10/12/2021 | Maintained | Outperform | 48 | |
| 8/6/2021 | Maintained | Market PerformPerform | – | |
| 8/6/2021 | Maintained | Outperform | 48 | |
| 3/2/2021 | Downgrade | BuyHold | – | |
| 3/2/2021 | Downgrade | OutperformPerform | – | |
| 3/2/2021 | Downgrade | OutperformPerform | 61 | |
| 3/2/2021 | Downgrade | OverweightNeutral | 61 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Athenex Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/26/2023 | -0.09USD | - | -USD | - | 2023 Q2 |
| 5/8/2023 | -0.09USD | - | -USD | - | 2023 Q1 |
| 3/13/2023 | -0.09USD | - | 30.12 MUSD | - | 2022 Q4 |
| 11/3/2022 | -0.15USD | - | 29.36 MUSD | - | 2022 Q3 |
| 7/28/2022 | -0.15USD | - | 31.73 MUSD | - | 2022 Q2 |
| 5/10/2022 | -0.19USD | - | 25.80 MUSD | - | 2022 Q1 |
| 3/16/2022 | -0.18USD | - | 40.87 MUSD | - | 2021 Q4 |
| 11/4/2021 | -0.38USD | - | 24.38 MUSD | - | 2021 Q3 |
| 8/5/2021 | -0.37USD | - | 23.79 MUSD | - | 2021 Q2 |
| 5/6/2021 | -0.41USD | - | 24.90 MUSD | - | 2021 Q1 |
Athenex shareholder structure
| % | Name |
|---|---|
0.49338% | |
0.20698% | |
0.17036% | |
0.13633% | |
0.09163% | |
0.06353% |
Athenex Beneficial Ownership Filings (SEC 13D/G)
Frequently asked questions about Athenex
Athenex Inc is a pharmaceutical company based in the United States. It was founded in 2003 by Dr. Johnson Lau and Dr. Rudolf Kwan. The company specializes in the discovery, development, and commercialization of innovative oncology drugs. Athenex Inc has a diverse pipeline of products, including oral chemotherapy drugs, immunotherapy agents, and targeted therapies. The company has strategic partnerships with various institutions, including the Buffalo Medical Innovation and Commercialization Hub, which aids in the development and manufacturing of its products. With a strong focus on research and development, Athenex Inc continues to strive towards improving treatment options for cancer patients.
The business model of Athenex Inc revolves around the development and commercialization of innovative therapies for cancer treatment. The company focuses on both oral and injectable oncology drugs that address unmet medical needs. Athenex employs a vertically integrated approach, combining its research and development capabilities with manufacturing and commercialization expertise. By leveraging its proprietary technology platforms, including Orascovery and Src Kinase Inhibition, Athenex aims to enable more effective and targeted cancer treatments. This strategic model allows the company to bring novel therapies to market more efficiently and broaden its product portfolio, ultimately improving patient outcomes.
Athenex Inc is primarily active in the biopharmaceutical and oncology industries. The company focuses on the development and commercialization of innovative therapies to treat cancer and other diseases. Athenex is committed to advancing medical science and improving patient outcomes through its research and development efforts. With its expertise in the field, Athenex aims to provide effective and safe treatment options for patients globally.
The main competitors of Athenex Inc in the market are pharmaceutical companies such as AstraZeneca, Pfizer, and Novartis.
Athenex Inc. has achieved several significant milestones in its operations. The company received FDA approval for its oral paclitaxel and encequidar in metastatic breast cancer, providing a new treatment option for patients. Athenex Inc. also secured a strategic partnership with Almirall to commercialize and develop its KX2-391 and KX-01 drugs for the treatment of actinic keratosis and cutaneous squamous cell carcinoma. Furthermore, the company witnessed the successful completion of a Phase III study on oral paclitaxel in gastric cancer, demonstrating positive outcomes. These milestones showcase Athenex Inc.'s dedication to advancing innovative treatments and expanding its therapeutic portfolio.
Athenex Inc is primarily present in the United States and various regions within Asia. The company has a strong presence in China, often referred to as its core market, where it operates multiple facilities and has established partnerships. Additionally, Athenex Inc has a significant presence in other Asian countries and regions such as Japan, Korea, and Southeast Asia. With its focus on developing and commercializing innovative oncology and immune-oncology products, Athenex Inc continues to expand its global footprint while maintaining a solid presence in the United States and key Asian markets.
Athenex Inc represents a commitment to innovation, integrity, and patient-centered care. The company aims to develop and deliver innovative therapies to improve the lives of patients around the world. With a strong focus on research and development, Athenex Inc prioritizes groundbreaking solutions in the fields of oncology and immunology. Their corporate philosophy emphasizes collaboration, excellence, and a passion for scientific advancements. By harnessing cutting-edge technologies and fostering strategic partnerships, Athenex Inc strives to address unmet medical needs and make a positive impact in the healthcare industry.
9 analysts currently rate the Athenex stock: 6 recommend buying, 3 holding and 0 selling.
The Athenex share (ATNX) is listed on 4 stock exchanges, including: NASDAQ (ATNX), Frankfurt (2MT.F), München (2MT.MU), Düsseldorf (2MT.DU).
Athenex Inc. is an American biopharmaceutical company specializing in the development and manufacture of innovative drugs for cancer and other diseases. Athenex has various divisions focusing on research and development, pharmaceutical manufacturing, marketing and sales, and biopharmaceutical services. The company uses novel technologies and scientific knowledge in the development of its drugs and has several medications in clinical trials, including oral cancer drugs and specialized antibiotics. Athenex operates state-of-the-art manufacturing facilities in the U.S. and China, producing a wide range of pharmaceuticals. Its marketing and sales team distributes medications for cancer treatments and other diseases both domestically and internationally through strategic partnerships, direct sales, and online platforms. Additionally, Athenex offers biopharmaceutical services such as drug development, clinical trials, analysis, manufacturing, and quality assurance for other companies. The company's product offerings include oncology drugs, immunotherapies, and specialized antibiotics aimed at improving the lives of cancer patients, boosting treatment outcomes, combating antibiotic resistance, and developing new drugs for antibiotic-resistant bacteria strains. Athenex has a strong business model built on years of industry experience and a portfolio of innovative products and services, with a focus on meeting the needs of patients, doctors, and other stakeholders. The company will continue to invest in research and development to enhance its products and services and ensure future growth.
The revenue cannot currently be calculated for Athenex.
The profit cannot currently be calculated for Athenex.
The P/E ratio cannot be calculated for Athenex at the moment.
The P/S cannot be calculated for Athenex currently.
The Eulerpool Quality Score for Athenex is 2/10.
The ISIN of Athenex is US04685N1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Athenex is A2DTE9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Athenex is ATNX. The ticker symbol is used to trade Athenex shares on the stock exchange.
Athenex is assigned to the 'Health' sector.
The dividends of Athenex are distributed in USD.
Athenex stock
Athenex Ticker
Athenex FIGI
All fundamentals and in-depth analysis of Athenex
Our stock analysis for Athenex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athenex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.